Connor, Clark & Lunn Investment Management Ltd. Castle Biosciences Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 165,458 shares of CSTL stock, worth $4.13 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
165,458
Previous 66,887
147.37%
Holding current value
$4.13 Million
Previous $1.46 Million
224.04%
% of portfolio
0.03%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding CSTL
# of Institutions
201Shares Held
24.5MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$75.9 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$45.5 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$43.6 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$31.5 Million0.61% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.26MShares$31.3 Million2.85% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $656M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...